Archive for March, 2011

Internal J&J Emails Detail “Ugly” Chapter in Mismarketing of Antipsychotics

Friday, March 25th, 2011

BNET
By Jim Edwards
March 25, 2011

One of the reasons Johnson & Johnson (JNJ) lost a recent trial verdict over its misleading marketing of Risperdal was because jurors saw the company’s internal emails in which senior staff described their own actions as “ugly” and not “competent.”

Although the emails don’t reveal anything we don’t already know about Risperdal — J&J marketed the atypical antipsychotic for years by playing down the risk of weight gain and diabetes associated with the drug — the communications do give us a rare glimpse into the backbiting that happens inside drug companies when they fall afoul of the FDA. Pharmaceutical companies almost never discuss this kind of thing in public. (The documents can be downloaded at CourtroomView Network.)

In 2003, the FDA became increasingly concerned that use of drugs such as Risperdal and Eli Lilly (LLY)’s Zyprexa led to weight gain, diabetes and, in some patients, an early death. So it wrote to all antipsychotic drug companies to require them to send a “dear health care provider” letter to all U.S. doctors advising them of this risk:

But J&J began trying to figure out whether the “dear doctor letter” could actually be used to promote Risperdal, which executives believed was not as risky as similar drugs. SVP/R&D Scott Reines had seen a previous “dear doctor letter” from Eli Lilly that had used the same sleight of hand, and he asked a colleague, “how much commercial liability would we incur if we sent a similar letter about Risperdal”?:

When J&J’s letter went out, instead of heightening doctors’ awareness of the risk of diabetes it said the opposite: “Risperdal is not associated with an increased risk of diabetes”:

The FDA — unsurprisingly — hit the roof, and sent J&J a warning letter, blasting the company for being “false and misleading.”

Inside J&J, Reines was furious: “The whole management team almost got canned,” he wrote to chief medical officer Joanne Waldstreicher. “The warning letter is ugly … it’s really a black mark for J&J …  [and] no competent person would have let [the 'dear doctor letter'] go out”:

J&J faces up to $36 million in fines as a result.

Read article here:  http://www.bnet.com/blog/drug-business/internal-j-j-emails-detail-8220ugly-8221-chapter-in-mismarketing-of-antipsychotics/7743

« Return to news items


Share

Adderall’s on First, Ritalin’s on Second: The Ongoing Saga of PEDs in Baseball

Thursday, March 24th, 2011

Bleacher Report
By Joseph Jones
March 23, 2011

It seems like an eternity since Major League Baseball finally got around to admitting it had a problem of the performance enhancing variety, but in reality it has barely been a half a decade.

Players once thought to be first-ballot Hall of Famers are struggling to garner more than a pittance of support from sports writers and fans alike as the sport carries on the best it can.

Attendance remains high—despite an ongoing quasi-recession—television revenue is streaming in and it appears that many of the measures taken by commissioner Bud Selig and his merry band of nitwits salvaged what little dignity this great sport had left in the wake of all that ugliness.

But alas, as always, looks can be deceiving.

I, for one, was more than a little bit surprised when MLB decided to include a ban on stimulants in its new drug program a few years back.

Now the use of uppers is neither new nor surprising in the baseball world, going back as far as the days of Willie Mays players have been using some form or another to endure the grueling demands of the 162-game season.

While steroids, and their artificial augmentation of baseball’s favorite play, the longball, have received most of the mainstream media coverage, anyone who really knows two shits about baseball recognizes that “greenies” have always been a much more pervasive part of the game.

Countless stories of large Ronald Reagan-esque like jars filled with amphetamines (as opposed to Ronnie’s trademark jellybeans) and pots of coffee labeled “extra-caffeinated” could be found without much effort at all.

A baseball season is a long & grueling one, after all. 162 games, packed into about 180 days, taking players, coaches and fans through a hot and humid summer can wear down even the best of men.  So for decades players have turned to “artificial means” to carry them through the dog days of summer.

I told more than one friend that it would be interesting to see who “faded down the stretch” and chuckled at the sudden emergence of energy drinks as sponsors for the big league clubs.

But I never could have imagined the thing that would catch my eye exactly one year later…and every year since.

When the league banned these drugs, an amazing thing happened. The number of players claiming and obtaining “therapeutic use” exemptions for stimulants nearly quadrupled from 28 to 103.

“Therapeutic use” means you can justifiably use the drug because you need it for a medical condition. If you didn’t have the condition, you’d just be a normal pro baseball player, and the attention-focusing benefits of Ritalin would be a form of “enhancement,” i.e., cheating.

Before the ban only 28 players had “therapeutic use exemptions” allowing them to take drugs such as Ritalin or Adderall.  Twenty-eight.  Then somehow magically that number jumps to over 100 as soon as the ban kicks in?

Color me suspicious but do they really think we are that dumb?

I mean how the hell can ADHD multiply fourfold in a sport in a single year? How can it become three times as prevalent in that sport as in the adult population? Is it contagious? Can Derek Jeter give it to Dustin Pedroia if he coughs on him as he slides into second base?  Of course not.

ADHD is a psychological diagnosis. Like post-traumatic stress disorder or bipolar disorder it’s open to interpretation in any given patient. Three doctors may say you don’t have it. A fourth may say you do.

It’s that subjectivity that should have led to the league having a more discerning eye. After all they had literally just caught the foxes trying to rob the hen house when they found over 100 major leagues had tested positive in their last round of anonymous testing.

MLB should have also taken notice of what pretty much EVERYONE else had when these numbers were first published, namely that among adults, the rate of diagnosis is between 1 percent and 3.5 percent. But among pro baseball players, the disease seems epidemic.  That means 8 percent of major-league players have ADHD—twice the rate among children and three to eight times the rate among adults.

But, of course, they didn’t.

They argue that once the number spiked up to 103 it “plateaued” and has remained at or about that same level since.  This is true, the numbers show there were 105 therapeutic use exemptions in 2010, up from 106 TUEs in 2008/2009 and 103 in 2007, but it still doesn’t address why there was such a sharp rise in the first place.

But then again, do we really expect more from Bud the Dud?

The World Anti-Doping Agency sure as hell doesn’t:

“My reaction is the same as last year and the year before that,” said Dr. Gary Wadler, chairman of the committee that determines the banned substances list for the World Anti-Doping Agency. “It seems to me almost incomprehensible that ADHD is so pervasive in baseball to a degree that it requires medicine.”

A frequent critic of baseball’s drug-testing program, Wadler said “these numbers really cry out for transparency in the TUE process in baseball — a good look-see at the process, not just the numbers.”

This ostrich-like ability of Selig’s, where he is able to shove his head in the sand for unnaturally long periods of time has long infuriated me frankly.

I only wish I could have been a fly-on-the-wall in the offices of Major League Baseball when the recent divorce proceedings of Kansas City Royals catcher Jason Kendall and his estranged wife Chantel have remained frequent fodder for internet gossip sites like TMZ and RadarOnline and even recently made the jump to websites not concerned with the latest atrocious parenting of Jon and Kate Gosselin.

While professional athletes ditching gold digging trophy wives is no novel concept, this one had steamy particulars involving the love triangle of a pro athlete, a smokin’ hot babe and the son of a rock-n-roll legend (Chantel is currently dating Sean Stewart, son of Rod Stewart).

The focus of the tittle-tattle involved Chantel accusing her husband of abusing the drug Adderall, which subsequently led to him both physically and emotionally abusing her.

Aside from accusations that he urinated & defecated on a pile of Chantel’s clothes after finding out she had been cheating on him, she claimed that he received a spurious prescription to take what is now labeled a performance enhancing drug otherwise banned by Major League Baseball.

While Kendall refused to answer the judge’s question about his use of greenies under the argument that (I. shit. you. not) Mark McGwire didn’t have to answer the questions he was asked in court about PEDs, he was very forthcoming about his prescription drug habits and more than willing to toss former teammates Brian Giles and Bobby Crosby under the bus, implicating them as fellow Adderall appreciators in court depositions.

One has to think that Bud was running around Manhattan looking for a schoolyard sandbox the shove his head in the moment he caught wind of these proceedings.

I am sure Selig is a good man. It appears he has a passion for baseball, and genuinely wants to do the right thing to help the sport.  But there is a problem—he is gutless.

For years he ignored steroids in baseball while the problem grew out of control.  Despite many fans knowing certain players were on steroids, even going back to the 1980s (for an example, a 1988 Fenway Park crowd chanted “Ster-oids” at Jose Canseco), Selig in February of 2005 said, with a straight face:

“I never heard about it.  I ran a team and nobody was closer to their players and I never heard any comment from them.  It wasn’t until 1998 or ’99 that I heard the discussion…I don’t know if there were allegations in the early 90s.  I never heard them.”

I remember reading those comments and thinking either this man is absolutely lying, or he is completely incompetent and oblivious.  Maybe it is a little of both, but either way, this man should not be allowed to run major league baseball.

Further, even if taken at face value, if Selig knew about steroids in 1998 or ’99, why did it take him until 2005 to take any action, and only after Congress forced him into it.

Sadly, I fully expect this same sort of blissful ignorance to plague Selig’s handling of this next round of PEDs in baseball.

Just as stories about players juicing were swept under the rug because of increasing television ratings and attendance due to historical records falling every year, this dirty little secret will go on flying under the radar.

Instead of looking out for the interest and integrity of the game, Selig will gladly keep trading it  away, piece by piece, for an increased revenue stream.

Read article here:  http://bleacherreport.com/articles/643751-adderalls-on-first-ritalins-on-second

« Return to news items


Share

J&J Duped South Carolina Doctors Over Risperdal, Lawyer Says

Wednesday, March 23rd, 2011

Bloomberg Business Week – March 23, 2011

By Jef Feeley and Gary Henderson

Johnson & Johnson executives deceived South Carolina doctors about the safety of the antipsychotic drug Risperdal, and the drugmaker should be held liable for that deception, a lawyer said.

J&J made misleading claims about Risperdal’s health risks and effectiveness in a letter to more than 7,000 South Carolina doctors and that violated consumer protection laws, John Simmons, a lawyer for the state, said in closing arguments of the trial of a lawsuit seeking at least $360 million in penalties.

The drugmaker, based in New Brunswick, New Jersey, used “unfair and deceptive acts” in a marketing campaign designed to dupe doctors into signing off on Risperdal for mental-health patients, Simmons told jurors today.

The state’s case centers on drug-safety claims that J&J and its Ortho-McNeil-Janssen Pharmaceuticals unit made in November 2003 correspondence to 700,000 doctors across the U.S., including 7,200 in South Carolina. The U.S. Food and Drug Administration responded with a warning letter saying J&J made false and misleading claims that minimized the potentially fatal risks of diabetes and overstated the drug’s superiority to those from competitors.

J&J contends the state hasn’t proved the company set out to mislead doctors about Risperdal or started a “spin campaign” to bolster sales of the drug, Steven J. Pugh, one of the drugmaker’s lawyers, said in his closing statement.

Fall in Sales

South Carolinians with mental-health issues “have benefited from Risperdal,” Pugh said. “You haven’t heard that anyone in South Carolina has been harmed by Risperdal.”

Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. It generated $3.4 billion in sales in 2008, or 5.4 percent of J&J’s total sales, according to company filings. Sales of the drug fell to $527 million last year, according to a January earnings report.

Risperdal Consta, the long-acting version of the antipsychotic drug, generated $1.5 billion in sales last year for Johnson & Johnson, officials said this month.

Under South Carolina’s unfair trade practices law, if jurors decide Johnson & Johnson deceived doctors about Risperdal in the 2003 letter, the company can be fined as much as $5,000 for each letter. Judge Roger Couch will decide the financial- penalty issue after jurors hand down their decision.

Third Jury Trial

The case is the third of about 10 state lawsuits to be considered by jurors over J&J’s Risperdal marketing campaigns. In June, J&J won dismissal of Pennsylvania’s suit alleging the company hid the drug’s diabetes risk and tricked regulators into paying millions more than they should have for the medicine.

A Louisiana jury ordered the drugmaker in October to pay $257.7 million in damages to that state for making misleading claims about Risperdal’s safety. A judge later added $73 million in legal fees to the award.

A West Virginia judge in a 2009 non-jury trial awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. The state dropped its Risperdal claim after J&J won an appeal, company officials said in February.

J&J’s Risperdal letter to doctors was part of a campaign to protect billions of dollars in sales of the antipsychotic drug and showed a lack of concern for the safety of South Carolina patients who took the drug, Simmons said.

The drugmaker set up a “spin machine” to deceive doctors about the drug and hid studies casting doubt on the medication’s safety and effectiveness, the lawyer said. “It was all about the money,” he added.

‘Send a Message’

“You have the power to send a message to these companies that you can’t hide stuff,” Simmons said. “Tell them, no unethical, immoral conduct in South Carolina.”

The Risperdal letter in the state’s crosshairs isn’t a proper basis for the attorney general’s claims that the drugmaker violated consumer-protection laws, Pugh countered.

The FDA warned J&J in 2004 to correct some things in the letter, but never formally sanctioned the drugmaker for sending it out, the lawyer added.

“The November 2003 letter was true then and it’s true now,” Pugh said. Risperdal is different from other antipsychotic medicines and “doctors needed to know that,” he added.

Jurors will begin deliberating the case tomorrow.

Read the rest of the article here: http://www.businessweek.com/news/2011-03-21/j-j-duped-south-carolina-doctors-over-risperdal-lawyer-says.html

« Return to news items


Share

American Psychiatric Association Slammed by Disease Mongering Parody Featuring Instant Disease Generation Engine

Wednesday, March 23rd, 2011

Saleonl.com, March 23, 2011
By Steve Diaz

click image for Disease Mongering Engine

The American Psychiatric Association is under fire today by an independent health news site’s launch of the “Disease Mongering Engine” – an online tool that allows users to instantly generate disorders, dysfunctions and syndromes that sound real, but aren’t.

Available at www.NewsTarget.com, the Disease Mongering Engine was created by Mike Adams, a vocal critic of modern psychiatric medicine and its practice of labeling healthy people with fictitious diseases, then over-medicating them with patented pharmaceuticals.

“Modern psychiatry has lost its way and has now become a marketing branch of Big Pharma,” Adams said. “Convincing healthy people that they’re diseased, then harming them with unsafe chemical medications, is not a legitimate approach to health and healing.” Diseases ranging from ADHD to Social Anxiety Disorder were “invented” by drug companies and psychiatrists, Adams says, as a way to generate billions of dollars in profits by selling treatment drugs and services to people who don’t need them.

The Disease Mongering Engine is capable of generating more than 73,000 unique disease names. Disease definitions are also generated using advanced linguistic modeling that results in real-sounding disease explanations using words and phrases found in the American Psychiatric Association’s DSM-IV, the “bible” of psychiatric disorders.

In initial testing, the engine randomly generated more than 25 disorders that are actually listed in the DSM-IV and used by psychiatrists to diagnose children and adults.

Humorous disease names generated by the Disease Mongering Engine include Repetitive Erectile Sleepwalking Dysfunction (RESD), Repetitive Manic Identity Syndrome With Anxiety (RMISWA) and Intermittent Dysmorphic Eating Dysfunction With Indigestion (IDEDWI). Users can generate more fictitious diseases at: http://www.newstarget.com/disease-mongering-engine.asp

« Return to news items


Share

California claims drug giant bribed docs to prescribe

Wednesday, March 23rd, 2011

Ventura County Star, March 22, 2011

Associated Press

photo by Boaz Yiftach

LOS ANGELES – California has joined a whistleblower lawsuit that claims Bristol-Myers Squibb Co. bribed doctors to prescribe its drugs, costing insurers perhaps millions of dollars in the largest alleged health care fraud case ever handled by the state, Insurance Commissioner Dave Jones announced Friday.

The suit claims company salespeople plied physicians with speaking fees, expensive meals, gifts and trips to induce or reward them for prescribing large amounts of its drugs, which were billed to private insurers.

For example, the company invited doctors to attend Los Angeles Lakers games at Staples Center and spent thousands of dollars on luxury suites, the suit claimed.

“Golf outings, basketball camps, samba lessons, you name it,” Jones said at a news conference.

The lawsuit said the aim was to boost prescription levels for legally approved and so-called “off-label” uses of drugs ranging from the antipsychotic Abilify to the blood thinner Plavix.

The company is accused of setting up a speakers bureau that doled out thinly veiled kickbacks in the form of cash payments to influential or high-prescribing doctors for speaking about its products.

One doctor received a $2,500 honorarium even though he never actually spoke, Jones said.

The company denied any wrongdoing.

“Bristol-Myers Squibb believes this lawsuit has no merit and the company will defend itself vigorously,” said Laura Hortas, a company spokeswoman.

California joined a 2007 lawsuit filed by one current and two former employees of the pharmaceutical giant. If they win, the whistleblowers and the state would share damages.

The amended complaint was filed by state insurance department lawyers two weeks ago in Los Angeles Superior Court.

It’s not the first time New York-based Bristol-Myers Squibb has been accused of kickbacks by its own workers.

In 2007, the company agreed to pay $515 million to settle federal lawsuits brought by whistleblowers in Massachusetts and Florida.

The current lawsuit says the company tracked prescription figures, and low-prescribing doctors were threatened with loss of perks.

A sales plan entitled “Rounding Up the Docs!” instructed salespeople at dinner events to get physicians to commit to prescribing for specific types of patients and to monitor the number of new prescriptions by doctors. the suit states.

The company is believed to have made at least 15,000 kickbacks from 1999 to 2005, and investigators suspect that the practice is continuing, Jones said.

The cost of the alleged practice was unclear, but Jones noted the size of the previous federal settlement.

No doctors have been sued or charged with a crime because the insurance department is focusing on the company in its civil action.

The suit seeks unspecified damages that include a $10,000 fine for each prescription obtained through fraud and repayment of any profit the company made from the alleged scheme.

The investigation was continuing.

« Return to news items


Share

Panel to Examine Murder and Suicide Associated With Antidepressants

Tuesday, March 22nd, 2011

The Huffington Post, March 22, 2011
by Dr. Peter Breggin

Click image to visit the Psychiatric Drug Database

On Saturday morning April 9th of this year, a panel discussion will be held for the public and professionals on the theme of “Psychiatric Drug Tragedies: Personal, Legal and Medical Perspectives.”

The two-hour presentation focuses on suicide and murder potentially caused by antidepressant medications. It is part of the international Empathic Therapy Conference put on by the Center for the Study of Empathic Therapy, Education & Living (April 8-10, 2011 in Syracuse, New York).

The panel will present a unique examination of an antidepressant-related suicide from three perspectives: Mathy Downing, the mother of a twelve-old-child who committed suicide; Karl Protil, the lawyer in her case, which was settled without any admission of negligence; and myself as the medical expert in the case. Mathy will be accompanied by her surviving daughter. Other family members will tell the stories of two more children who committed suicide, a father who committed suicide, and a husband who murdered his two young children–all while taking prescribed antidepressants.

A great deal is now known about suicide and violence in association with the newer antidepressants such as Prozac (fluoxetine), Paxil (paroxetine), Zoloft (sertraline), Luvox (fluvoxamine), Celexa (escitalopram), Lexapro (escitalopram), Cymbalta (duloxetine), Effexor (venlavaxine), Pristiq desvenlafaxine), and Wellbutrin (bupropion).

The FDA has imposed a Black Box on all antidepressant labels that warns against the risk of suicidal behavior in children, youth and young adults. Click here to find the example of Prozac’s official prescribing information. More importantly and more broadly, the new labels also warn about the risk of aggression, hostility, mania, and an overall worsening of the individual’s mental condition, for all ages. The new FDA-approved labels also include a Medication Guide, which the FDA urges prescribers to give to patients and their families. Originally intended for children taking antidepressants, it now has no age limitation and pertains to all ages. The Medication Guide warns patients and their families to be aware of the possibility of suicidal and violent behavior, mania, and a long litany of other dangerous mental abnormalities.

The new FDA-approved antidepressant labels confirm that the risks are highest at the start of medication therapy or during changes in dose, either up or down. To a great extent, the labels read like my prior publications, one of which was given by the FDA to its outside expert committee that recommended the changes to the labels.

Unfortunately, many psychiatrists, internists, family doctors, nurse practitioners and other professionals continue to prescribe these medications, too often without providing adequate information to the patient and the family. As a result, I was asked to write about the implications of these new labels for the most widely read psychiatric journal for primary care prescribers. The panel at the Empathic Therapy Conference, the first of its kind, will explore these tragedies and put a human face on them through the presence and presentations of surviving family members.

Other aspects of the conference will describe empathic approaches to helping a wide variety of emotional conditions and problems in children and adults. Speakers will bring unique and inspiring approaches to children and adults given psychiatric diagnoses, ordinary folks who are suffering from stress, street people overcome by psychosis, military personnel recovering from PTSD and head injuries, and elderly victims of dementia. Professionals and the general public are welcome at the Empathic Therapy Conference in Syracuse, New York, April 8-10, 2011. Continuing education credits (CEs) for 29.5 hours are available.

Peter R. Breggin, MD is a psychiatrist in private practice in Ithaca, New York, and the author of dozens of scientific articles and more than twenty books including Toxic Psychiatry: Why Therapy, Empathy and Love Must Replace the Drugs, Electroshock and Biochemical Theories of the “New” Psychiatry, as well as his newest book, Medication Madness. The Empathic Therapy Conference brings together more than forty presenters and a diverse audience from around the world. Professionals and nonprofessionals are welcome. Learn about the conference at http://www.empathictherapy.org.

« Return to news items


Share

Psychiatric drug industry driven by wealth and stealth, not mental health

Tuesday, March 22nd, 2011

Natural News
By Monica Young
March 22, 2011

Drug company corporate websites tell us of their integrity and utmost commitment to people’s health and well-being. The American Psychiatric Association’s website begins with “Healthy Minds. Healthy Lives” and asserts the “highest ethical standards of professional conduct.” Yet a mountain of evidence points to an entirely different picture.

Most recently, thirty-eight state attorneys won a $68.5 million settlement with pharmaceutical titan AstraZeneca for unlawful marketing of antipsychotic Seroquel for unapproved use. These states also charged this company with failing to disclose the drug’s harmful side effects and concealing negative information about its safety and efficacy. “The company’s illegal practices put our most vulnerable populations at risk, including children and older patients with dementia and other debilitating diseases,” states Illinois Attorney General. U.S. sales of Seroquel brought in $5.3 billion for AstraZeneca last year.

Looking further, it’s evident that the pharmaceutical industry is fraught with fraud. For instance, the new generation of antipsychotics is the single biggest target of the False Claims Act. Every major drug company selling the drugs has either settled recent government cases for hundreds of millions of dollars or is under investigation for health care fraud.

Psychiatric drugs are notoriously high-priced. A year’s supply of one top antipsychotic is $7,000. A recent Biosocieties (scientific journal) article, entitled, “Demythologizing the high costs of pharmaceutical research,” exposes that drug companies widely exaggerate research costs to justify these prices. These companies typically cite a 2003 industry-funded study to claim a tag of over $1 billion to research and bring a drug to market. A new independent analysis indicates the figure is closer to $55 million.

Meanwhile drug company CEOs are some of the most excessively paid CEOs on Wall Street. Johnson & Johnson CEO’s publicly reported total compensation for 2009 (the last report available) was $25.6 million, including salary, bonus, stock options and other perks. This is three times the average for CEOs of S&P 500 companies and over 500 times the median American household income. His base salary was raised this year, despite an ongoing lawsuit, backed by the Department of Justice, accusing J&J of involvement in a kickback scheme to push their antipsychotic on elderly nursing home residents.

Drug manufactures spend billions yearly on marketing and advertising, far beyond what they spend on research. Billions go into direct to consumer advertising which drums a mantra to the masses: “ask your doctor if (___ medication) is right for you.” Billions are poured into marketing to doctors, including via drug sales reps – one of the most lucrative sales jobs in the U.S.

One ex-drug sales rep, Shahram Ahari, told a Senate Aging Committee that on top of a base salary for starting reps of $50,000, “there were four quarterly bonuses, an annual bonus, stock options, a car, 401k, great health benefits, and a $60,000 expense account.” He said his job involved “rewarding physicians with gifts and attention for their allegiance to your product and company despite what may be ethically appropriate.”

Another former drug sales rep and author of Confessions of an RX Drug Pusher, Gwen Olsen, says it’s all about the money. She described her hiring process. When asked why she wanted to become a pharmaceutical sales rep, she said she wanted to help people. The regional manager replied, “If that’s the case, you might want to join the Peace Corps…But if money is what motivates you, young lady, let me tell you how you can retire a millionaire.” Gwen reports that every manager she worked for said children are their biggest and most profitable expansion market.

Psychiatrists cash in big time as drug-pushers. The faster they shuffle people in and out for 15-minute medication management visits, the more they fill their deep pockets.

A recent New York Times article “Talk Therapy Doesn’t Pay, So Psychiatry Turns Instead to Drug Therapy,” gives an example of a practicing psychiatrist since 1972. He likens his office now to a bus station. In the old days of 45-minute talk sessions, “he knew his patients’ inner lives better than he knew his wife’s; now, he often cannot remember their names,” states the author. The doctor admits, “I had to train myself not to get too interested in their problems.”

And how much does the average psychiatrist make a year peddling drugs? $191,000.

Worldwide sales of antidepressants, stimulants, antianxiety and antipsychotic drugs exceed $82 billion a year. Yet for all the wealth this has brought these industries, are people truly getting better?

Psychiatric drugs have repeatedly proven to not only be extremely hazardous to one’s health but can be life-threatening and even fatal. Now the Archives of General Psychiatry has released scientific proof that antipsychotic drugs shrink brain tissue. (No wonder psychiatrists are called “shrinks”!)

Science journalist and author, Robert Whitaker, reports that long-term use of psychiatric medications is actually causing more mental illness – not less. He states “what you find with them when you look at long term outcomes, you see more people having chronic symptoms long term than you do in the unmedicated.”

Whitaker also points to disability statistics. Since the boom of psychiatric prescriptions began in 1987, adults on disability for mental illness more than tripled to 4 million. Amongst those on disability, the percentage of children has risen from about 5% in 1987 to over 50% today.

Of course the pill-pushers and their hordes of paid lobbyists, advocacy groups and spokesmen want us to believe that this means more mentally ill are finally getting the drug treatment they really need.

But who wants to believe a bunch of liars anyway?

« Return to news items


Share

25 Good Reasons Why Psychiatry Must Be Abolished

Monday, March 21st, 2011

by Don Weitz, Psychiatric Survivor & 24-year activist in the psychiatric liberation movement

1. Because psychiatrists frequently cause harm, permanent disabilities, death – death of the body-mind-spirit.

2. Because psychiatrists frequently violate the Hippocratic Oath which orders all physicians “First Do No Harm.”

3. Because psychiatrists patronize and dis-empower people, especially their patients.

4. Because psychiatry is not a medical science.

5. Because psychiatry is quackery, a pseudo-science which lacks independent diagnostic tests, testable hypotheses, and cures for “schizophrenia” and all other types of alleged “mental illness” or “mental disorder”.

6. Because psychiatrists can not accurately and reliably predict dangerousness, violence, or any other type of human behaviour, yet make such claims as “expert witnesses”, and with the media promote the “dangerous mental patient” myth/stereotype.

7. Because psychiatrists have caused a worldwide epidemic of brain damage by promoting and prescribing brain-disabling treatments such as the neuroleptics, antidepressants, electroconvulsive brainwashing (electroshock), and psychosurgery (lobotomy).

8. Because psychiatrists manufacture hundreds of “mental disorders” classified in its bible called “Diagnostic and Statistical Manual of Mental Disorders” (a modern witch-hunting manual); such “mental disorders” and “symptoms” are in fact negative, class-and-culturally-biased moral judgments for dissident ways of coping with personal problems and alternative ways of perceiving, interpreting or being in the world.

9. Because psychiatrists, blinded by their medical model bias, fraudulently pathologize and label people’s serious life or existential crises as “symptoms” of “mental illness” or “mental disorder” such as “schizophrenia”, “bipolar affective disorder”, and “personality disorder”.

10. Because psychiatrists compound this fraud by falsely claiming, without scientific proof, that these “mental disorders” are caused by a “biochemical imbalance” in the brain, genetic factors or “genetic predispositions”, despite the fact that there are no genetic factors in “mental illness”.

11. Because psychiatrists frequently misinform their patients, families and the public by claiming that brain-disabling procedures such as the neurotoxins (e.g., “antipsychotic medication” and “antidepressants”), electroconvulsive brainwashing (electroconvulsive therapy/”ECT”), psychosurgery (lobotomy) and other behaviour modification-mind control procedures are “safe, effective and lifesaving”.  The exact opposite is tragically true.

12. Because psychiatrists routinely deceive or lie to patients, prisoners, their families, and the public.

13. Because psychiatrists routinely and willfully violate the medical-ethical principle of “informed consent” by misinforming or not informing their patients about the numerous toxic, disabling and frequently permanent effects of the neuroleptics such as memory loss, tardive dyskinesia, tardive psychosis, parkinsonism, dementia (all signs of brain damage), and death.

14. Because psychiatrists routinely threaten, intimidate or coerce many patients – particularly women, children, the elderly, and prisoners – into consenting to health-threatening/brain-damaging “treatment” such as the antidepressants, neuroleptics, electroconvulsive brainwashing, and hi-risk experiments.

15. Because psychiatrists frequently fail to fully inform psychiatric inmates and prisoners about existing safe and humane, non-medical alternatives in the community such as survivor-controlled crisis centres, drop-ins, self-help or advocacy groups, diet, massage, wholistic medicine, affordable supportive housing, and jobs.

16. Because psychiatrists are sexist in frequently stereotyping women in crisis as “hysterical” or “over-emotional”, blaming women whenever they voice real complaints and assertively express their feelings and emotions, prescribing massive doses of tranquilizers and antidepressants to disproportionately large numbers of women, and in sexually assaulting women in their offices and institutions.

17. Because psychiatrists, particularly white male psychiatrists, are homophobic – the American Psychiatric Association (APA) once labelled homosexuality as a “mental illness” or “mental disorder” – and have used forced electroshock on lesbians, trying to coerce them into adopting a heterosexual life style.

18. Because psychiatrists are ageist in prescribing tranquilizers, antidepressants (“medication”) and electroconvulsive brainwashing for disproportionately large numbers of elderly people – a form of elder abuse.

19. Because psychiatrists are racist in disproportionately incarcerating and drugging people of African descent, aboriginal people, other people of colour and labelling them “psychotic” or “schizophrenic”.

20. Because psychiatrists routinely violate people’s civil rights, human rights and constitutional rights such as imprisoning innocent people without court trial or public hearing (“involuntary commitment”), and subjecting them to cruel and unusual punishments or tortures such as forced drugging, electroconvulsive brainwashing, psychosurgery, solitary confinement, “chemical restraints”, and 4-point or 5-point restraints.

21. Because psychiatrists masterminded the mass murder of hundreds of thousands of vulnerable people including disabled children, the elderly and psychiatric patients during The Holocaust in Nazi Germany, and “selected” hundreds of thousands of concentration camp prisoners for death (“T-4 euthanasia” program) – historical facts still missing in psychiatric textbooks and histories.

22. Because psychiatrists have willingly participated in and administered mind-control experiments in the United States and Canada since the early 1950s – its chief targets have been poor patients, women, dissidents and prisoners.

23. Because psychiatry, particularly institutional-biological psychiatry, is based on the 3 Fs: Fear, Fraud, and Force.

24. Because psychiatry is a form of social control or punishment – not treatment.

25. Because psychiatry, particularly institutional-biological psychiatry, is fascist – a direct threat to democracy, human rights and life.

A note from the author: This statement is a slightly revised version of the original written in spring 1998.  Feel free to add and publish your own reasons.  I am a psychiatric survivor and antipsychiatry activist who has been involved in the psychiatric survivor liberation movement for 24 years.  I am also co-editor of “Shrink Resistant: The Struggle Against Psychiatry in Canada” (1988), host-producer of the antipsychiatry program “Shrinkrap” on CKLN radio (88.1 FM) in Toronto, member of People Against Coercive Treatment (P.A.C.T.), and member of the Ontario Coalition Against Poverty (OCAP).

PLEASE SNOWBALL, COPY AND PUBLISH THIS STATEMENT INCLUDING THE NOTE. NO COPYRIGHT OR PERMISSION REQUIRED.

RETURN TO BLOGS PAGE


Share

Psychiatry’s Billing Bible, the DSM: The Debate over Diagnosis

Monday, March 21st, 2011

Montreal Gazette
By Donna Nebenzahl

Psychiatric disorders are not discovered in labs, they are voted into existence by the American Psychiatric Association

Expected to be published in May 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – the bible of the American Psychiatric Association – has created a firestorm of controversy in its suggested treatment of individuals who have gender identity issues.

According to the manual, an individual questioning gender identity and meeting certain criteria suffers from gender identity disorder, which is therefore considered a mental disorder. And the new edition, whose revisions have been in the works for more than a decade, is likely to once again disappoint the vocal community that has been arguing for years that being transgendered is not a mental illness. (Preliminary revisions for DSM-5 are available for review at www.DSM5.org.)

Many medical practitioners and activists argue that the inclusion of gender identity disorder, even in its likely DSM-5 configuration as gender incongruence, “pathologizes a normal variant of human sexuality,” as Fordham University researcher Sarah Kamens wrote recently in the magazine of the Society for Humanistic Psychology.

“In the DSM that’s currently in use, it’s classified the same way homosexuality was 30 years ago,” says Dr. Shuvo Ghosh, who treats children with gender identity issues at the Montreal Children’s Hospital.

“The diagnosis stigmatizes trans people; it makes it look like they’re mentally ill, and they’re not,” says Françoise Susset, psychologist and president-elect of the Canadian Professional Association for Transgender Health. “Many of the people I see are very high functioning and have no mental illness whatsoever.”

“It’s being called a disorder and treated as a disorder, and I would say it should stay there,” argues Dr. Pierre Assalian, head of the human sexuality unit at the Montreal General Hospital. “I would say that until we find something biological that explains why somebody feels wrong in their body, I would have to consider it as a disorder.”

The research on biological underpinnings of gender identity issues is being carried out around the world, but in the meantime the American Psychiatric Association’s manual, considered the No. 1 source of diagnostic categories, maintains the condition’s psychiatric listing – with some troubling inclusions. One group of professionals proposed online that new indicators in the DSM-5 such as “strong preference for toys and games of the other gender . and playmates of the other gender” should be struck from the forthcoming manual, since preference for play and playmates, they argue, have “no place in diagnostic criteria for a psychiatric disorder.” http://www.montrealgazette.com/health/Debate+over+Diagnosis/4469318/story.html#ixzz1HFmnUm00

« Return to news items


Share

California Official Accuses Bristol Bristol-Myers Squibb of Bribing Doctors to Prescribe Drugs

Friday, March 18th, 2011

Los Angeles Times, March 18, 2011

By Duke Helfand and Marc Lifsher

Pharmaceutical giant Bristol-Myers Squibb bribed thousands of California doctors and pharmacists to promote its drugs, using illegal kickbacks, lavish gifts and “happy hours” with the Los Angeles Lakers to expand its market share in the state, state officials said.

California Insurance Commissioner Dave Jones announced Friday that his office had joined a previously sealed whistleblower lawsuit against the company, calling it the largest health insurance fraud case ever pursued by a California state agency.

Two of the three whistleblowers in the case are former Lakers player Lucius Allen and his wife, Eve, who worked for the drug company as employees and provided access to the basketball team, whose players participated in “Lakers Dream Camps” set up by the drug company for doctors and their family members, the lawsuit said. The lawsuit was filed in 2007 but was sealed until the state joined the case recently.

New York-based Bristol-Myers Squibb issued a statement: “Bristol-Myers Squibb believes this lawsuit has no merit and the company will defend itself vigorously.”

The case is the latest major legal action against Bristol-Myers Squibb over allegations of fraud. The pharmaceutical giant paid $515 million in 2007 to settle allegations by the federal government and other states that it used a kickback scheme to defraud the Medicare and Medicaid insurance programs, officials said.

The California lawsuit alleges that Bristol-Myers Squibb targeted the private insurance industry, making thousands of payments to “high prescribing doctors” who wrote prescriptions for its well-known drugs, including Plavix, Abilify and Pravachol.

Jones said that insurance companies in California had spent more than $3.5 billion to cover the costs of the drugs Bristol-Myers Squibb sought to promote through its kickback scheme.

“We need to be sure that doctors are prescribing drugs because those drugs are best for their patients and not because a pharmaceutical company provided doctors with trips and kickbacks,” Jones said. “These illegal practices drive up the cost of health insurance for millions of Californians.”

http://www.latimes.com/business/la-fi-drug-kickbacks-20110319,0,5610786.story

« Return to news items


Share